BMRN
Price:
$66.97
Market Cap:
$12.76B
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcu...[Read more]
Industry
Biotechnology
IPO Date
1999-07-26
Stock Exchange
NASDAQ
Ticker
BMRN
According to BioMarin Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 4.27. This represents a change of -51.44% compared to the average of 8.80 of the last 4 quarters.
The mean historical Current Ratio of BioMarin Pharmaceutical Inc. over the last ten years is 3.66. The current 4.27 Current Ratio has changed 11.57% with respect to the historical average. Over the past ten years (40 quarters), BMRN's Current Ratio was at its highest in in the December 2023 quarter at 25.11. The Current Ratio was at its lowest in in the December 2019 quarter at 2.08.
Average
3.66
Median
3.58
Minimum
2.08
Maximum
6.05
Discovering the peaks and valleys of BioMarin Pharmaceutical Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 128.32%
Maximum Annual Current Ratio = 6.05
Minimum Annual Increase = -59.55%
Minimum Annual Current Ratio = 2.08
Year | Current Ratio | Change |
---|---|---|
2023 | 2.51 | -46.25% |
2022 | 4.67 | 10.90% |
2021 | 4.21 | -11.40% |
2020 | 4.76 | 128.32% |
2019 | 2.08 | -47.00% |
2018 | 3.93 | 45.38% |
2017 | 2.70 | -16.48% |
2016 | 3.24 | 32.31% |
2015 | 2.45 | -59.55% |
2014 | 6.05 | -2.56% |
The current Current Ratio of BioMarin Pharmaceutical Inc. (BMRN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
3.80
5-year avg
3.65
10-year avg
3.66
BioMarin Pharmaceutical Inc.’s Current Ratio is greater than Seagen Inc. (2.67), greater than Alnylam Pharmaceuticals, Inc. (2.75), greater than Exelixis, Inc. (3.93), less than Halozyme Therapeutics, Inc. (10.36), less than Arrowhead Pharmaceuticals, Inc. (6.74), greater than Incyte Corporation (1.87), less than Ionis Pharmaceuticals, Inc. (8.91), less than Apellis Pharmaceuticals, Inc. (4.36), less than Vaxcyte, Inc. (17.88), less than Liquidia Corporation (6.33), less than Legend Biotech Corporation (4.98), less than Bio-Techne Corporation (4.56), less than Mereo BioPharma Group plc (6.10), greater than Blueprint Medicines Corporation (3.32), less than Agios Pharmaceuticals, Inc. (8.99), less than Day One Biopharmaceuticals, Inc. (14.62), less than IVERIC bio, Inc. (18.63), less than Amylyx Pharmaceuticals, Inc. (4.55), less than Karuna Therapeutics, Inc. (19.31),
Company | Current Ratio | Market cap |
---|---|---|
2.67 | $43.15B | |
2.75 | $31.44B | |
3.93 | $9.64B | |
10.36 | $6.01B | |
6.74 | $2.44B | |
1.87 | $13.45B | |
8.91 | $5.76B | |
4.36 | $4.11B | |
17.88 | $10.70B | |
6.33 | $974.17M | |
4.98 | $5.97B | |
4.56 | $11.58B | |
6.10 | $585.67M | |
3.32 | $5.71B | |
8.99 | $1.96B | |
14.62 | $1.28B | |
18.63 | $5.51B | |
4.55 | $276.25M | |
19.31 | $12.60B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioMarin Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioMarin Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is BioMarin Pharmaceutical Inc.'s Current Ratio?
How is the Current Ratio calculated for BioMarin Pharmaceutical Inc. (BMRN)?
What is the highest Current Ratio for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 3-year average Current Ratio for BioMarin Pharmaceutical Inc. (BMRN)?
What is the 5-year average Current Ratio for BioMarin Pharmaceutical Inc. (BMRN)?
How does the current Current Ratio for BioMarin Pharmaceutical Inc. (BMRN) compare to its historical average?